Literature DB >> 8893154

Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis.

M Hida1, Y Aiba, S Sawamura, N Suzuki, T Satoh, Y Koga.   

Abstract

The plasma levels of phenol, p-cresol, and indican are markedly increased in uremic patients, and cannot be efficiently reduced by hemodialysis. Such uremic toxins, which are produced in the intestine as bacterial putrefactive metabolites, accumulate to a great degree in the feces of hemodialysis patients. Oral administration of Lebenin, a preparation consisting of antibiotic-resistant lactic acid bacteria, reduced the levels of fecal putrefactive metabolites to levels comparable with those of healthy subjects. Moreover, the plasma level of indican also significantly decreased in these Lebenin-treated patients. An analysis of the fecal microflora revealed that a disturbed composition of the microflora characterized by an overgrowth of aerobic bacteria is restored to normal by oral administration of Lebenin in hemodialysis patients. These results thus demonstrate that oral administration of lactic acid bacteria in uremic patients is effective in reducing the levels of uremic toxins, especially that of indican, in the blood by inhibiting bacterial production by means of correcting the intestinal microflora.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8893154     DOI: 10.1159/000189334

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  84 in total

1.  Prevention of nephrolithiasis by Lactobacillus in stone-forming rats: a preliminary study.

Authors:  Cheol Kwak; Byong Chang Jeong; Ja Hyeon Ku; Hyeon Hoe Kim; Jeong Jun Lee; Chul Sung Huh; Young Jin Baek; Sang Eun Lee
Journal:  Urol Res       Date:  2006-04-22

Review 2.  Normal and pathologic concentrations of uremic toxins.

Authors:  Flore Duranton; Gerald Cohen; Rita De Smet; Mariano Rodriguez; Joachim Jankowski; Raymond Vanholder; Angel Argiles
Journal:  J Am Soc Nephrol       Date:  2012-05-24       Impact factor: 10.121

Review 3.  Probiotics and chronic kidney disease.

Authors:  Laetitia Koppe; Denise Mafra; Denis Fouque
Journal:  Kidney Int       Date:  2015-09-16       Impact factor: 10.612

4.  Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.

Authors:  Kyra J Barnes; Andrew Rowland; Thomas M Polasek; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2014-06-24       Impact factor: 2.953

Review 5.  Microbiota issue in CKD: how promising are gut-targeted approaches?

Authors:  Carmela Cosola; Maria Teresa Rocchetti; Alice Sabatino; Enrico Fiaccadori; Biagio Raffaele Di Iorio; Loreto Gesualdo
Journal:  J Nephrol       Date:  2018-08-01       Impact factor: 3.902

Review 6.  Clinical and experimental use of probiotic formulations for management of end-stage renal disease: an update.

Authors:  Alessandro Di Cerbo; Federica Pezzuto; Lucia Palmieri; Valentina Rottigni; Tommaso Iannitti; Beniamino Palmieri
Journal:  Int Urol Nephrol       Date:  2013-04-13       Impact factor: 2.370

Review 7.  Gut Microbiome in Chronic Kidney Disease.

Authors:  R G Armani; A Ramezani; A Yasir; S Sharama; M E F Canziani; D S Raj
Journal:  Curr Hypertens Rep       Date:  2017-04       Impact factor: 5.369

Review 8.  Effects of gluten-free, dairy-free diet on childhood nephrotic syndrome and gut microbiota.

Authors:  Natalie Uy; Lauren Graf; Kevin V Lemley; Frederick Kaskel
Journal:  Pediatr Res       Date:  2014-10-13       Impact factor: 3.756

Review 9.  Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis.

Authors:  Natalia Lucía Rukavina Mikusic; Nicolás Martín Kouyoumdzian; Marcelo Roberto Choi
Journal:  Pflugers Arch       Date:  2020-02-17       Impact factor: 3.657

10.  p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients.

Authors:  Björn K I Meijers; Henriette De Loor; Bert Bammens; Kristin Verbeke; Yves Vanrenterghem; Pieter Evenepoel
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-15       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.